Nov 11 (Reuters) – Amgen said on Wednesday its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren’s disease, an autoimmune condition.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
